Biogen | BIIB - Current Liabilities


Biogen reported $3.35B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
AbbVie USD 43.29B 3.9B Dec/2025
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Bayer EUR 32.58B 3.63B Dec/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 300.81M 58.22M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Puma Biotechnology USD 82.73M 3.63M Sep/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Teva Pharmaceutical Industries USD 13.46B 1.96B Dec/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
United Therapeutics USD 560.6M 14.3M Dec/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025